Ovarian Cancer

Carboplatin regimen better tolerated in patients with advanced disease

Published in Women's Health Weekly, September 25th, 2003

The chemotherapy regimen of carboplatin plus paclitaxel is as effective as cisplatin plus paclitaxel, but the carboplatin-paclitaxel regimen is associated with better tolerability and quality of life, according to a study from the Ovarian Cancer Study Group in Germany.

Ovarian cancer is rarely cured and more than 50% of patients die within 5 years of being diagnosed with the disease. Earlier studies had suggested that carboplatin plus paclitaxel might be better tolerated than cisplatin plus paclitaxel. To test this hypothesis, Andreas du Bois, MD, PhD, of the Dr. Horst Schmidt Hospital in Wiesbaden, Germany, and colleagues performed a randomized, Phase III clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry